INTRODUCTION AND OBJECTIVE: Although advanced age doesn't seem to impair oncological outcomes after robot-assisted radical prostatectomy (RARP), elderly patients have increased rates of prostate cancer (PCa) related deaths due to a higher incidence of high-risk disease. The potential unfavorable impact of advanced age on oncological outcomes following RARP remains an unsettled issue. We aimed to evaluate the oncological outcome of PCa patients > 69 years old in a single tertiary center. MATERIALS AND METHODS: 1143 patients with clinically localized PCa underwent RARP from January 2013 to October 2020. Analysis was performed on 901 patients with available follow-up. Patients ≥ 70 years old were considered elderly. Unfavorable pathology included ISUP grade group > 2, seminal vesicle, and pelvic lymph node invasion. Disease progression was defined as biochemical and/or local recurrence and/or distant metastases. RESULTS: 243 cases (27%) were classified as elderly patients (median age 72 years). Median (IQR) follow-up was 40.4 (38.7-42.2) months. Disease progression occurred in 159 cases (17.6%). Elderly patients were more likely to belong to EAU high-risk class, have unfavorable pathology, and experience disease progression after surgery (HR = 5.300; 95% CI 1.844-15.237; p = 0.002) compared to the younger patients. CONCLUSIONS: Elderly patients eligible for RARP are more likely to belong to the EAU high-risk category and to have unfavorable pathology that are independent predictors of disease progression. Advanced age adversely impacts on oncological outcomes when evaluated inside these unfavorable categories. Accordingly, elderly patients belonging to the EAU high-risk should be counseled about the increased risk of disease progression after surgery.
INTRODUCTION AND OBJECTIVE: Although advanced age doesn't seem to impair oncological outcomes after robot-assisted radical prostatectomy (RARP), elderly patients have increased rates of prostate cancer (PCa) related deaths due to a higher incidence of high-risk disease. The potential unfavorable impact of advanced age on oncological outcomes following RARP remains an unsettled issue. We aimed to evaluate the oncological outcome of PCa patients > 69 years old in a single tertiary center. MATERIALS AND METHODS: 1143 patients with clinically localized PCa underwent RARP from January 2013 to October 2020. Analysis was performed on 901 patients with available follow-up. Patients ≥ 70 years old were considered elderly. Unfavorable pathology included ISUP grade group > 2, seminal vesicle, and pelvic lymph node invasion. Disease progression was defined as biochemical and/or local recurrence and/or distant metastases. RESULTS: 243 cases (27%) were classified as elderly patients (median age 72 years). Median (IQR) follow-up was 40.4 (38.7-42.2) months. Disease progression occurred in 159 cases (17.6%). Elderly patients were more likely to belong to EAU high-risk class, have unfavorable pathology, and experience disease progression after surgery (HR = 5.300; 95% CI 1.844-15.237; p = 0.002) compared to the younger patients. CONCLUSIONS: Elderly patients eligible for RARP are more likely to belong to the EAU high-risk category and to have unfavorable pathology that are independent predictors of disease progression. Advanced age adversely impacts on oncological outcomes when evaluated inside these unfavorable categories. Accordingly, elderly patients belonging to the EAU high-risk should be counseled about the increased risk of disease progression after surgery.
Authors: Leah Y Nakamura; Rafael N Nunez; Paul E Andrews; Robert G Ferrigni; Mitchell R Humphreys; Scott K Swanson; Christopher E Wolter; Erik P Castle Journal: J Robot Surg Date: 2011-02-05
Authors: Marco Sebben; Alessandro Tafuri; Aliasger Shakir; Marco Pirozzi; Tania Processali; Riccardo Rizzetto; Nelia Amigoni; Leone Tiso; Mario De Michele; Andrea Panunzio; Clara Cerrato; Matteo Brunelli; Filippo Migliorini; Giovanni Novella; Vincenzo De Marco; Salvatore Siracusano; Walter Artibani; Antonio Benito Porcaro Journal: World J Urol Date: 2020-01-24 Impact factor: 4.226
Authors: Samer L Traboulsi; David-Dan Nguyen; Ahmed S Zakaria; Kyle W Law; Hanna Shahine; Malek Meskawi; Cristina Negrean; Pierre I Karakiewicz; Assaad El Hakim; Kevin C Zorn Journal: World J Urol Date: 2020-02-07 Impact factor: 4.226
Authors: A Kumar; S Samavedi; A S Bates; Camilo A Giedelman Cuevas; R F Coelho; B Rocco; K Palmer; V R Patel Journal: Eur J Surg Oncol Date: 2015-04-25 Impact factor: 4.424
Authors: Pratik M S Gurung; Bokai Wang; Stephen Hassig; Jasmine Wood; Elizabeth Ellis; Changyong Feng; Ahmed E Ghazi; Jean V Joseph Journal: World J Urol Date: 2020-06-14 Impact factor: 4.226